Literature DB >> 7777156

Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine.

M Cador1, Y Bjijou, L Stinus.   

Abstract

The repeated administration of amphetamine in rats produces behavioral sensitization which is characterized either by a progressive enhancement of the locomotor activity induced by the drug or by an enduring behavioral hypersensitivity to the drug after the cessation of the treatment. Some authors have suggested that the action of amphetamine at the level of the nucleus accumbens is responsible for the expression of behavioral sensitization, whereas the action of amphetamine at the level of the dopamine cell bodies in the ventral tegmental area induces some changes responsible for the initiation of the phenomenon. The present study fully tested this hypothesis. In two separate experiments, the effects of different doses of amphetamine repeatedly administered in the ventral tegmental area or in the nucleus accumbens were tested on the later behavioral reactivity to the administration of amphetamine in the nucleus accumbens. Independent groups of rats received five repeated administrations (one injection every other day) of different doses of amphetamine either in the ventral tegmental area (0, 1, 2.5, 5 micrograms/0.5 microliters per side) or in the nucleus accumbens (0, 1, 3, 10 micrograms/l microliters per side). Two days following the last intracerebral amphetamine injection, each group received a phosphate buffer solution challenge directly into the nucleus accumbens followed two days later by an amphetamine challenge (1 microgram/l microliters per side) in the nucleus accumbens and two days later by a peripheral challenge with amphetamine (0.5 mg/kg, s.c.). Locomotor responses were recorded following each injection. Results showed that injections of amphetamine into the nucleus accumbens induced a dose-dependent increase in locomotor activity which remained identical with the repetition of the injections. No difference between the different intra-accumbens pretreated groups was observed following the diverse phosphate-buffered saline solution and amphetamine challenges. In contrast, intra-ventral tegmental area administration of amphetamine did not produce any modification of locomotor activity. However, whereas no difference between the differently pretreated groups was observed following phosphate-buffered saline administration into the nucleus accumbens, a potentiation of the locomotor response to a challenge dose of amphetamine into the nucleus accumbens was observed which was dependent on the dose of amphetamine pretreatment into the ventral tegmental area. Similar potentiation was observed following peripheral challenge with amphetamine. Finally, cross-sensitization was observed when a challenge dose of cocaine (10 micrograms/1 microliter per side) was injected into the nucleus accumbens, as well as when a peripheral challenge dose of morphine (2.5 mg/kg, s.c.) was administered to the ventral tegmental area-pretreated groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777156     DOI: 10.1016/0306-4522(94)00524-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  43 in total

1.  The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system.

Authors:  Heather N Lavezzi; Daniel S Zahm
Journal:  Basal Ganglia       Date:  2011-11

2.  Appetitive sensitization by amphetamine does not reduce its ability to produce conditioned taste aversion to saccharin.

Authors:  John Scott-Railton; Gretchen Arnold; Paul Vezina
Journal:  Behav Brain Res       Date:  2006-10-04       Impact factor: 3.332

3.  Potentiating effect of tramadol on methamphetamine-induced behavioral sensitization in mice.

Authors:  Jian-Hui Liang; Keng Wang; Hong-Lei Sun; Rong Han
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

4.  Corticotropin releasing factor-1 receptor antagonist, CP-154,526, blocks the expression of ethanol-induced behavioral sensitization in DBA/2J mice.

Authors:  J R Fee; D R Sparta; M J Picker; T E Thiele
Journal:  Neuroscience       Date:  2007-09-08       Impact factor: 3.590

5.  Regulation of netrin-1 receptors by amphetamine in the adult brain.

Authors:  L Yetnikoff; C Labelle-Dumais; C Flores
Journal:  Neuroscience       Date:  2007-10-10       Impact factor: 3.590

6.  The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization.

Authors:  Juuso Juhila; Antti Haapalinna; Jouni Sirviö; Jukka Sallinen; Aapo Honkanen; Esa R Korpi; Mika Scheinin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-14       Impact factor: 3.000

7.  Activation of afferents to the ventral tegmental area in response to acute amphetamine: a double-labelling study.

Authors:  Joyce Colussi-Mas; Stefanie Geisler; Luc Zimmer; Daniel S Zahm; Anne Bérod
Journal:  Eur J Neurosci       Date:  2007-08       Impact factor: 3.386

8.  VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation.

Authors:  Carolina Birgner; Karin Nordenankar; Martin Lundblad; José Alfredo Mendez; Casey Smith; Madeleine le Grevès; Dagmar Galter; Lars Olson; Anders Fredriksson; Louis-Eric Trudeau; Klas Kullander; Asa Wallén-Mackenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  Social stress and CRF-dopamine interactions in the VTA: role in long-term escalation of cocaine self-administration.

Authors:  Christopher O Boyson; Elizabeth N Holly; Akiko Shimamoto; Lucas Albrechet-Souza; Lindsay A Weiner; Joseph F DeBold; Klaus A Miczek
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

10.  Central administration of p-hydroxyamphetamine produces a behavioral stimulant effect in rodents: evidence for the involvement of dopaminergic systems.

Authors:  Hiroshi Onogi; Masato Hozumi; Osamu Nakagawasai; Yuichiro Arai; Seiichiro Ishigaki; Atsushi Sato; Seiichi Furuta; Fukie Niijima; Koichi Tan-No; Takeshi Tadano
Journal:  Psychopharmacology (Berl)       Date:  2009-12-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.